Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of the clinical study was to see if applying low level laser light therapy to the breasts during breast implant surgery could lessen pain experienced by 24 hours after the surgery.
Substantial pain, discomfort and swelling following breast augmentation surgery is not uncommon. The ability of low level laser therapy to reduce swelling and inflammation that subsequently reduces pain has been well documented. This study aimed to evaluate the ability of low level laser therapy to reduce post-operative pain and swelling for individuals undergoing bilateral breast augmentation surgery, by 24 hours post-surgery.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Placebo Laser | Sham Comparator | Placebo Laser is an inactive light |
|
| Erchonia EML Laser | Active Comparator | Erchonia EML Laser uses two 7mW red 635nm wavelength light emitting CSRH Class IIIb laser diodes. The energy delivered is 1.5 J/cm2. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Erchonia(R) EML Laser | Device | Low level laser red light of 635 nm and delivering 1.5 joules/cm2. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants Who Scored Less Than 30 on the 0-100 Visual Analog Scale (VAS)for Pain 24 Hours Post-operative. | Self-reported Degree of Pain rating using the standardized 0-100 Visual Analog Scale (VAS) scale provided at 24 hours post-implant procedure, at which time the subject will not have taken any pain medication for at least four hours. The VAS ratings range from 0 to 100, where '0' represents 'no pain at all' and '100' represents 'worst pain imaginable.' A VAS of 30 is indicated as a cutoff threshold for 'success.' Participants who recorded a VAS rating of less than 30 were considered study 'successes' and are reported below. | 24 hours post-operative |
| Self-reported Pain Rating on the 0-100 VAS 24 Hours Post-operative. | Self-reported Degree of Pain rating using the standardized 0-100 VAS scale provided at 24 hours post-implant procedure, at which time the subject will not have taken any pain medication for at least four hours. VAS values range from '0' representing 'no pain at all' to '100' representing 'worst pain imaginable.' | 24 hours |
| Measure | Description | Time Frame |
|---|---|---|
| Swelling Evaluation Through Length by Width Breast Diameter Measurements | immediately, 24 hours & 7 days post surgery | |
| Self-reported Degree of Pain Rating in the Breasts Area. | 24 hours, 7 days, 14 days & 28 days post surgery |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Breast augmentation procedures indicated for the purpose of breast reconstruction following mastectomy or an injury due to severe trauma.
Presence of a specific connective tissue disorder.
Inadequate tissue available to cover the implants.
Consumption of any one or more of narcotics, opiates, and/or steroids.
Inability to consume the following medications post-operatively due to allergy, intolerance, or any other reason:
(i) Pain medication for the relief of post-operative pain of Lortab 10/500 or another drug within the combination narcotic analgesic drug category within which Lortab falls.
(ii) Antibiotic medication for reducing the risk of post-operative infection of Keflex 500 mg or Cipro 500 mg or another drug within the broad-spectrum antibiotic drug category within which Keflex and Cipro fall.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Robert F Jackson, MD, FACS | Principal Investigator | |
| Gregory Roche, DO | Principal Investigator | |
| Thomas L Jackson, MD | Principal Investigator |
Not provided
Not provided
| Label | URL |
|---|---|
| FDA 510(k)#K072206 clearance listing resulting from the outcome of this study | View source |
Not provided
There were no significant events or approaches for the study following participant enrollment and prior to group assignment. All enrolled participants proceeded to group assignment.
The recruitment period was from 9/30/05 - 6/28/07 at private practice test site locations.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Placebo Laser | inactive light |
| FG001 | Erchonia(R) EML Laser | The Erchonia(R) EML Laser uses two 7mw red 635nm wavelength light emitting CSRH Class IIIb laser diodes. The energy delivered is 1.5 J/cm2. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Placebo Laser | inactive light |
| BG001 | Erchonia(R) EML Laser | The Erchonia(R) EML Laser uses two 7mw red 635nm wavelength light emitting CSRH Class IIIb laser diodes. The energy delivered is 1.5 J/cm2. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Participants Who Scored Less Than 30 on the 0-100 Visual Analog Scale (VAS)for Pain 24 Hours Post-operative. | Self-reported Degree of Pain rating using the standardized 0-100 Visual Analog Scale (VAS) scale provided at 24 hours post-implant procedure, at which time the subject will not have taken any pain medication for at least four hours. The VAS ratings range from 0 to 100, where '0' represents 'no pain at all' and '100' represents 'worst pain imaginable.' A VAS of 30 is indicated as a cutoff threshold for 'success.' Participants who recorded a VAS rating of less than 30 were considered study 'successes' and are reported below. | ITT Analysis with LOCF technique employed, as applicable. | Posted | Number | participants | 24 hours post-operative |
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Placebo Laser | inactive light |
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Elvira Walls, Clinical Consultant | Regulatory Insight, Inc. | 615-712-9743 | elvira@reginsight.com |
Not provided
| ID | Term |
|---|---|
| D010146 | Pain |
| ID | Term |
|---|---|
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo Laser | Device | Inactive light |
|
| Use of Pain Management Medication Post-surgically. | Average number of rescue pain medication doses consumed across the 1st 7 post-operative days. | Through the 1st 7 post-operative days. |
| Hydration Level Assessment | immediately, 24 hours & 7 days post surgery. |
| Infection Evaluation | 24 hours & 7 days post surgery |
| Wound Healing Evaluation According to the Modified Hollander Cosmesis Scale | 7 days post surgery |
| BG002 | Total | Total of all reporting groups |
| Participants |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| OG001 |
| Erchonia(R) EML Laser |
The Erchonia(R) EML Laser uses two 7mw red 635nm wavelength light emitting CSRH Class IIIb laser diodes. The energy delivered is 1.5 J/cm2. |
|
|
|
| Secondary | Swelling Evaluation Through Length by Width Breast Diameter Measurements | Not Posted | immediately, 24 hours & 7 days post surgery |
| Secondary | Self-reported Degree of Pain Rating in the Breasts Area. | Not Posted | 24 hours, 7 days, 14 days & 28 days post surgery |
| Secondary | Use of Pain Management Medication Post-surgically. | Average number of rescue pain medication doses consumed across the 1st 7 post-operative days. | ITT with LOCF | Posted | Mean | Standard Deviation | medication doses | Through the 1st 7 post-operative days. |
|
|
|
|
| Secondary | Hydration Level Assessment | Not Posted | immediately, 24 hours & 7 days post surgery. |
| Secondary | Infection Evaluation | Not Posted | 24 hours & 7 days post surgery |
| Secondary | Wound Healing Evaluation According to the Modified Hollander Cosmesis Scale | Not Posted | 7 days post surgery |
| Primary | Self-reported Pain Rating on the 0-100 VAS 24 Hours Post-operative. | Self-reported Degree of Pain rating using the standardized 0-100 VAS scale provided at 24 hours post-implant procedure, at which time the subject will not have taken any pain medication for at least four hours. VAS values range from '0' representing 'no pain at all' to '100' representing 'worst pain imaginable.' | Intention to treat (ITT) analysis with imputation technique of Last Observation Carried Forward (LOCF). | Posted | Mean | Standard Deviation | scores on a scale | 24 hours |
|
|
|
|
| 0 |
| 54 |
| 0 |
| 54 |
| EG001 | Erchonia(R) EML Laser | The Erchonia(R) EML Laser uses two 7mw red 635nm wavelength light emitting CSRH Class IIIb laser diodes. The energy delivered is 1.5 J/cm2. | 0 | 50 | 0 | 50 |
Not provided
Not provided